Gammagard is a prescription immunoglobulin therapy used to treat three FDA-approved conditions: primary immunodeficiency, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. It works by delivering concentrated antibodies collected from donated human plasma, either replacing antibodies your body can’t make on its own or calming an overactive immune system that’s attacking your nerves.
The Three FDA-Approved Uses
Gammagard Liquid carries FDA approval for three distinct conditions, each involving a different problem with the immune system.
Primary immunodeficiency (PI) is the broadest indication. People with PI have immune systems that don’t produce enough protective antibodies, leaving them vulnerable to frequent and sometimes dangerous infections. Gammagard serves as replacement therapy, supplying the antibodies their bodies can’t make. It’s approved for adults and children aged two and older.
Multifocal motor neuropathy (MMN) is a rare condition where the immune system attacks the nerves controlling your muscles, causing progressive weakness, usually starting in the hands and arms. Gammagard is approved as ongoing maintenance therapy to improve muscle strength and reduce disability in adults with MMN.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is another nerve condition driven by immune system dysfunction. In CIDP, the immune system damages the protective coating around peripheral nerves, leading to weakness, numbness, and difficulty walking. Gammagard is approved to improve neuromuscular disability and impairment in adults with CIDP.
How Gammagard Works in the Body
Gammagard is made from pooled human plasma and contains a concentrated mix of immunoglobulin G (IgG), the most abundant type of antibody in the bloodstream. For patients with primary immunodeficiency, the mechanism is straightforward: the infusion delivers the antibodies they lack, raising their blood levels high enough to fight off infections the way a healthy immune system would.
For nerve conditions like MMN and CIDP, the mechanism is more complex. Rather than simply replacing something missing, the flood of donated antibodies appears to modulate the immune system, essentially dialing down the misdirected immune attack on nerve tissue. The exact pathways are still being studied, but the clinical effect is measurable: patients retain more strength and function when they stay on regular infusions.
How It’s Given
Gammagard Liquid can be administered two ways: intravenously (directly into a vein) or subcutaneously (injected just under the skin). The route you use affects how often you receive treatment.
Intravenous infusions are typically given every three to four weeks at a clinic or infusion center. Each session can last several hours depending on the dose and how quickly your body tolerates the infusion rate. Subcutaneous infusions are given more frequently, often weekly, but at smaller doses each time. Many patients learn to do subcutaneous infusions at home, which offers more flexibility and avoids repeated trips to a clinic.
When switching from intravenous to subcutaneous delivery, the dose is recalculated. The initial subcutaneous dose is roughly 1.37 times the previous intravenous dose, divided across the weeks between infusions. From there, doctors adjust based on how you’re responding and your antibody levels on blood tests.
Off-Label Uses in Neurology and Autoimmune Disease
Beyond its three approved indications, Gammagard and other immunoglobulin products are frequently prescribed off-label for a wide range of neurological and autoimmune conditions. This is common practice across medicine and reflects the broad immune-modulating effects of immunoglobulin therapy.
Conditions where doctors may prescribe immunoglobulin therapy off-label include Guillain-Barré syndrome, myasthenia gravis, multiple sclerosis, dermatomyositis and polymyositis, stiff person syndrome, certain forms of epilepsy, and autoimmune encephalitis, among others. The strength of evidence varies by condition, and insurance coverage for off-label use can be inconsistent. If your doctor recommends Gammagard for a condition not listed above, it’s worth asking about the evidence supporting that use and whether your insurance plan will cover it.
Common Side Effects During Infusion
Most side effects from Gammagard are mild and temporary, resembling flu-like symptoms. Flushing, headache, fatigue, fever, chills, nausea, and general malaise are the most frequently reported reactions. These tend to occur during or shortly after the infusion and resolve on their own.
Infusion-related reactions are often managed by slowing the drip rate. Many clinics start with a slower rate for your first few infusions and gradually increase it as your body adjusts. Premedicating with common over-the-counter pain relievers or antihistamines before an infusion can also reduce symptoms. Serious reactions are rare but can include severe headaches, blood clots, and kidney problems, particularly in patients with preexisting risk factors like dehydration, kidney disease, or a history of clotting disorders.
Gammagard Liquid vs. Gammagard S/D
You may see two versions of Gammagard mentioned: Gammagard Liquid and Gammagard S/D. They’re both immunoglobulin products from the same manufacturer, but they differ in formulation. Gammagard Liquid contains no added sugars, while Gammagard S/D contains 2% glucose. Both have very low IgA content (less than 2 micrograms per milliliter for Liquid, less than 1 for S/D), which matters for the small number of patients who have IgA deficiency and could react to higher IgA levels.
Gammagard Liquid is the more commonly prescribed version today and the one approved for all three indications discussed above. It’s also the formulation that can be given either intravenously or subcutaneously, giving patients and doctors more flexibility in how treatment fits into daily life.